2nd Quarter - Report

BROWNSTEIN HYATT FARBER SCHRECK, LLP for NOVARTIS

Firm
Client
Income
$100,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues related to cell and gene therapy and radioligand therapies Pharmaceutical pricing Issues related to the development of therapies for rare diseases 340B Drug Discount Program Supply chain issues affecting pharmaceutical products Implementation of the Inflation reduction Act Pharmaceutical innovation PBM policy issues HR 1672 The Maintaining Investments in New Innovations (MINI) Act Intellectual property Issues Tariff issues affecting the pharmaceutical industry EPIC Act

LobbyistCovered position, as disclosed
NADEAM ELSHAMI —
EMILY FELDER —
BRIAN THOMAS MCGUIRE —
ZACHARY PFISTER —
DAVID REID —
JOHN REISING New Scheduler, Operations Director, Member Services Director, Deputy Chief of Staff- Majority Leader Steve Scalise; Operations Director, Rep. Bill Flores; Scheduler, Rep. Austin Scott; Intern, Senator Trent Lott.
ADAM STEINMETZ —
GREGORY SUNSTRUM —
DEEMA TARAZI —
ANDREW USYK —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; U.S. Trade Representative (USTR)

Bills named: H.R. 1672 (119th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.